Based on 20 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $85.47 with a high forecast of $105.00 and a low forecast of $74.00. The average price target represents a 26.60% change from the last price of $67.51.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"68":"$68","87":"$87","106":"$106","77.5":"$77.5","96.5":"$96.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$85.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$74.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[68,77.5,87,96.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.78,72.48923076923077,75.19846153846154,77.90769230769232,80.61692307692307,83.32615384615384,86.03538461538461,88.74461538461539,91.45384615384616,94.16307692307691,96.87230769230769,99.58153846153846,102.29076923076923,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.78,70.98692307692308,72.19384615384615,73.40076923076923,74.6076923076923,75.81461538461538,77.02153846153846,78.22846153846154,79.43538461538462,80.6423076923077,81.84923076923077,83.05615384615385,84.26307692307692,{"y":85.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.78,70.10461538461539,70.42923076923077,70.75384615384615,71.07846153846154,71.40307692307692,71.72769230769231,72.05230769230769,72.37692307692308,72.70153846153846,73.02615384615385,73.35076923076923,73.67538461538462,{"y":74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":83.158,"date":1682035200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.029,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.663,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.012,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.213,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.521,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.349,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.606,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.771,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.041,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.389,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.722,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.78,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$105.00

Average Price Target$85.47

Lowest Price Target$74.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Cantor Fitzgerald

xxxxxxxxxxxxx

Reiterated

04/22/24

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Reiterated

04/19/24

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Reiterated

04/18/24

xxxxxxxxxxxxxxxxxx

Wells Fargo

xxxxxxxxxxxxx

Reiterated

04/17/24

xxxxxxxxxxxxxxxxxx

UBS

xxxxxxxxxxxxx

Reiterated

04/17/24

xxxxxxxxxxxxxxxxxx

Truist Financial

xxxxxxxxxxxxx

Initiated

04/15/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

04/11/24

xxxxxxxxxxxxxxxxxx

Morgan Stanley

xxxxxxxxxxxxx

Reiterated

04/09/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Reiterated

04/04/24

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

03/15/24

Evan Seigerman

BMO Capital

$89.00

Buy

31.83%

Upside

Reiterated

03/15/24

BMO Capital reiterates Outperform Rating on Gilead Sciences (GILD)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $89.00 price target on Gilead Sciences (NASDAQ: GILD).

Salim Syed

Mizuho Securities

$90.00

Buy

33.31%

Upside

Reiterated

03/15/24

Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD)

Michael Yee

Jefferies

$95.00

Buy

40.72%

Upside

Reiterated

03/14/24

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL)

Joseph Catanzaro

Piper Sandler

$95.00

Buy

40.72%

Upside

Assigned

03/11/24

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Crinetics Pharmaceuticals (NASDAQ: CRNX)

Michael Okunewitch

Maxim Group

$90.00

Buy

33.31%

Upside

Reiterated

02/13/24

Strategic Acquisition Bolsters Gilead's Liver Disease Portfolio: A Buy Rating Justified

Best Analysts Covering Gilead Sciences

Which Analyst Should I Follow If I Want to Buy GB:0QYQ and Sell After:

1 Month

Tyler Van BurenTD Cowen

Success Rate

11/21 ratings generated profit

Average Return

+0.67%

assigned a buy rating 3 months ago

Copying Tyler Van Buren's trades and holding each position for 1 Month would result in 52.38% of your transactions generating a profit, with an average return of +0.67% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Geoff MeachamBank of America Securities

Success Rate

10/19 ratings generated profit

Average Return

-0.34%

reiterated a buy rating last month

Copying Geoff Meacham's trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of -0.34% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Salim SyedMizuho Securities

Success Rate

31/57 ratings generated profit

Average Return

+5.67%

reiterated a buy rating last month

Copying Salim Syed's trades and holding each position for 1 Year would result in 54.39% of your transactions generating a profit, with an average return of +5.67% per trade.

2 Years

Hartaj SinghOppenheimer

Success Rate

19/30 ratings generated profit

Average Return

+9.83%

reiterated a buy rating 7 days ago

Copying Hartaj Singh's trades and holding each position for 2 Years would result in 63.33% of your transactions generating a profit, with an average return of +9.83% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QYQ Analyst Recommendation Trends

Rating

Dec 23

Jan 24

Feb 24

Mar 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QYQ has received 24 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. 0QYQ average Analyst price target in the past 3 months is $85.47.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0QYQ Financial Forecast

0QYQ Earnings Forecast

Next quarter’s earnings estimate for 0QYQ is -$1.51 with a range of -$1.86 to -$1.14. The previous quarter’s EPS was $1.72. 0QYQ beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 36.00% of the time in the same period. In the last calendar year 0QYQ has Underperformed its overall industry.

0QYQ Sales Forecast

Next quarter’s sales forecast for 0QYQ is $6.36B with a range of $5.97B to $6.78B. The previous quarter’s sales results were $7.11B. 0QYQ beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.84% of the time in the same period. In the last calendar year 0QYQ has Outperformed its overall industry.

0QYQ Stock Forecast FAQ

What is GB:0QYQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is $85.47.

What is GB:0QYQ’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 26.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gilead Sciences a Buy, Sell or Hold?

Gilead Sciences has a conensus rating of Moderate Buy, which is based on 9 buy ratings, 11 hold ratings and 0 sell ratings.

What is Gilead Sciences’s share price target?

The average share price target for Gilead Sciences is $85.47. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $105.00 ,and the lowest forecast is $74.00. The average share price target represents 26.60% Increase from the current price of $67.51.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Gilead Sciences?

To buy shares of GB:0QYQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Gilead Sciences (0QYQ) Share Forecast & Price Target

0QYQ Analyst Ratings

0QYQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

0QYQ Analyst Recommendation Trends

0QYQ Financial Forecast

0QYQ Earnings Forecast

0QYQ Sales Forecast

0QYQ Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts